Rotavirus vaccines - An update

Carl D. Kirkwood, Jim Buttery

Research output: Contribution to journalReview ArticleResearchpeer-review

21 Citations (Scopus)

Abstract

Rotavirus vaccines offer the best hope to reduce the toll of acute rotaviral gastroenteritis in both developed and developing countries. An association with intussusception (IS) led to the withdrawal of the first licensed rotavirus vaccine in the USA in 1999, forcing a re-evaluation of the safety profile of potentially lifesaving vaccines. Development of new rotavirus vaccine candidates has continued, with a bovine-human reassortant vaccine and an attenuated human monovalent vaccine commencing Phase III trials. Several other candidates are in early Phase I and II clinical trials. The creation of innovative funding strategies to support vaccine development and production, specifically in developing countries, aim to make vaccines available where rotavirus causes the greatest impact.

Original languageEnglish
Pages (from-to)97-105
Number of pages9
JournalExpert Opinion on Biological Therapy
Volume3
Issue number1
DOIs
Publication statusPublished - 1 Jan 2003
Externally publishedYes

Keywords

  • Immunisation
  • Rotavirus
  • Rotavirus vaccine
  • Vaccine

Cite this